Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in ALLO held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | PFIZER INC | 22.0M | $49.8M | 0.0% | 9.034% | 20.85% |
| 2 | BlackRock, Inc. | 19.1M | $46.6M | +8.0% | 7.828% | 0.00% |
| 3 | TPG GP A, LLC | 18.7M | $45.7M | 0.0% | 7.675% | 1.24% |
| 4 | STATE STREET CORP | 8.7M | $21.1M | +213.6% | 3.551% | 0.00% |
| 5 | PRIMECAP MANAGEMENT CO/CA/ | 8.4M | $20.4M | +2.9% | 3.436% | 0.02% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 6.9M | $16.9M | β | 2.838% | 0.00% |
| 7 | CITADEL ADVISORS LLC | 6.9M | $16.8M | -43.6% | 2.824% | 0.01% |
| 8 | TWO SIGMA INVESTMENTS, LP | 5.4M | $13.1M | +57.0% | 2.204% | 0.01% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 4.1M | $10.1M | +4.9% | 1.691% | 0.00% |
| 10 | Frazier Life Sciences Management, L.P. | 3.8M | $9.3M | -1.9% | 1.557% | 0.24% |
| 11 | Woodline Partners LP | 3.5M | $8.5M | +0.0% | 1.436% | 0.03% |
| 12 | Patient Square Capital LP | 3.5M | $8.4M | -30.5% | 1.415% | 1.49% |
| 13 | MARSHALL WACE, LLP | 3.4M | $8.4M | +1107.4% | 1.414% | 0.01% |
| 14 | MILLENNIUM MANAGEMENT LLC | 3.3M | $8.1M | +80.4% | 1.362% | 0.01% |
| 15 | Candriam Luxembourg S.C.A. | 3.0M | $7.3M | +30.0% | 1.229% | 0.04% |
| 16 | Wildcat Capital Management, LLC | 2.9M | $7.1M | 0.0% | 1.198% | 6.71% |
| 17 | GOLDMAN SACHS GROUP INC | 2.8M | $6.7M | +20.8% | 1.134% | 0.00% |
| 18 | D. E. Shaw & Co., Inc. | 2.8M | $6.7M | +115.4% | 1.133% | 0.01% |
| 19 | Boxer Capital Management, LLC | 2.7M | $6.6M | β | 1.117% | 0.87% |
| 20 | AQR CAPITAL MANAGEMENT LLC | 2.5M | $6.1M | +73.9% | 1.019% | 0.00% |
| 21 | Nuveen, LLC | 2.3M | $5.6M | +751.1% | 0.949% | 0.00% |
| 22 | MPM Oncology Impact Management LP | 2.2M | $5.5M | β | 0.920% | 0.42% |
| 23 | RENAISSANCE TECHNOLOGIES LLC | 2.1M | $5.2M | -2.2% | 0.877% | 0.01% |
| 24 | BANK OF AMERICA CORP /DE/ | 2.1M | $5.2M | +111.9% | 0.875% | 0.00% |
| 25 | JACOBS LEVY EQUITY MANAGEMENT, INC | 2.0M | $4.9M | β | 0.826% | 0.02% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in ALLO β a direct measure of their conviction.
Filings activity in ALLO during Q1 2026, grouped by how each filer changed its position.
Institutions that opened a new ALLO position in Q1 2026
Institutions that fully closed their ALLO position in Q1 2026
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 203 | +21% | 91.61% | +44.93 pp | $424M | +96% |
| Q4 2025 | 168 | +0.0% | 46.68% | +4.45 pp | $216M | +11% |
| Q3 2025 | 168 | +5.0% | 42.23% | 1.35 pp | $196M | 3.1% |
| Q2 2025 | 160 | 5.3% | 43.58% | 16.59 pp | $202M | 28% |
| Q1 2025 | 169 | 2.3% | 60.17% | 21.48 pp | $279M | 26% |
| Q4 2024 | 173 | +13% | 81.65% | 10.50 pp | $378M | 11% |
| Q3 2024 | 153 | 10% | 92.15% | +13.89 pp | $427M | +18% |
| Q2 2024 | 170 | β | 78.26% | β | $363M | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying ALLO stock.
Based on Q1 2026 13F filings, institutional ownership of Allogene Therapeutics, Inc. stands at 91.6%, held across 203 reporting institutions.
PFIZER INC is the largest reported institutional holder of ALLO, with approximately 22,032,040 shares worth $0.05B as of Q1 2026.
Yes β 4 widely-followed marquee investors appear among the top 25 institutional holders of ALLO, including CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP, MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC.
Our composite Smart Money Score for ALLO is 83 out of 100 (Strong Smart Money). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
51 institutions opened new positions in ALLO during Q1 2026, while 16 fully exited. 134 added to existing positions and 16 trimmed.
ALLO institutional ownership rose by 44.93 percentage points quarter-over-quarter, with a net change of +35 holders.
The top 10 institutions account for 58.8% of all reported 13F value in ALLO, and the top 25 account for 82.5%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Allogene Therapeutics, Inc. (ALLO) Institutional Ownership